Boston Scientific

Boston Scientific
VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.  Continue reading «Boston Scientific»

Website Share Login to Edit

Full Description

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. With 24,000 employees worldwide, sales force in 40+ countries, and 15 manufacturing facilities worldwide, the company invested $895 million in R&D in 2011, with a $7.6 billion revenue.

 

rel="nofollow"

Address

Boston Scientific Corporate Headquarters One Boston Scientific Place Natick, MA 01760-1537, USA

Phone

+1 (508) 650-8000

Twitter username

https://twitter.com/bostonsci


Company News

  • Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter

    New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology LISBON, Portugal and MARLBOROUGH, Mass., March 17, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal. The data demonstrated positive safety and efficacy results with the LUMINIZE™ Radiofrequency (RF) Balloon Catheter for isolation of pulmonary veins (PV) when treating patients with atrial fibrillation (AF).   Patients with arrhythmias such as AF are often treated with anti-arrhythmic d...
  • Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

    Company begins limited market release in Europe MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in Europe. Patients with AF are five times more likely to suffer a stroke than someone with a normal heart rhythm.1 In people with non-valvular atrial fibrillation (AF), data suggests that more than 90% of stroke-causing blood clots that come from the heart are formed in the left atrial appendage.2 The WATCHMAN left atrial appendage occlusion devices are intended to reduce the risk of stroke in ...
  • Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

    MARLBOROUGH, Mass., March 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on March 17-19. Two late-breaking clinical trials will be presented, including: Outcomes from AF-FICIENT I, a prospective, multicenter, single arm trial assessing the safety and efficacy of the LUMINIZE™ Radiofrequency (RF) Balloon Catheter for the treatment of atrial fibrillation (AF); New data on temporal association of AF with device-based heart failure status from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients...
  • Boston Scientific to Participate in the Cowen and Company 39th Annual Healthcare Conference

    MARLBOROUGH, Mass., Feb. 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston. Dan Brennan, executive vice president and chief financial officer, and Lindsay Fish, director, Investor Relations, will participate in a 30-minute question-and-answer session with the host analyst beginning at approximately 8:40 a.m. EDT.  A live webcast of the question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. A replay of the webcast will be accessible at...
  • Boston Scientific Completes $4.3 Billion Offering of Senior Notes and Issues Redemption Notice for its 2020 Notes

    MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 million of 4.550% notes due 2039 and $1.0 billion of 4.700% notes due 2049. The Company intends to use the net proceeds from the offering to (i) finance a portion of its previously announced proposed acquisition of BTG plc (the "BTG Acquisition"), (ii) redeem its 6.000% notes due January 2020 and its 2.850% notes due May 2020...
  • Boston Scientific Prices $4.3 Billion of Senior Notes

    MARLBOROUGH, Mass., Feb. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under the Company's shelf registration statement. The public offering consists of $850 million in aggregate principal amount of 3.450% notes due 2024, $850 million in aggregate principal amount of 3.750% notes due 2026, $850 million in aggregate principal amount of 4.000% notes due 2029, $750 million in aggregate principal amount of 4.550% notes due 2039 and $1.000 billion in aggregate principal amount of 4.700% notes due 2049. The company expects to receive the ...
  • Boston Scientific to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

    MARLBOROUGH, Mass., Feb. 14, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 in New York City. Joe Fitzgerald, executive vice president and president, Rhythm Management, and Susie Lisa, vice president, Investor Relations, will participate in a 25-minute question-and-answer session with the host analyst beginning at approximately 11:30 a.m. EST.  A live webcast of the question-and-answer session will be available on the Investor Relations section of the Boston Scientific website at investors.bostonscientific.com. A replay of the webcast...